Jackson Jamere, an insider at Eli Lilly and Co (LLY), purchased 9,635 shares of the company on November 16, 2025, at a price of $1,021.70 per share, amounting to a total transaction value of $9.84 million. Following this acquisition, Jamere now holds 9,635 shares of Eli Lilly.
Eli Lilly, a major player in the pharmaceuticals industry, is headquartered in Indianapolis, Indiana, and employs approximately 47,000 full-time staff. The company specializes in the discovery, development, manufacture, and sale of a wide range of pharmaceutical products, including treatments for cardiometabolic health, oncology, immunology, and neuroscience.
As of November 18, 2025, Eli Lilly boasts a market capitalization of $965.9 billion, a P/E ratio of 52.46, and an EPS of 20.45. The company has also announced upcoming earnings, with estimates of $7.86 per share and $18.7 billion in revenue for August 4, 2026, and $7.16 per share with $17.1 billion in revenue for April 28, 2026.
Insider buying can often signal confidence in a company's future prospects, as executives typically possess insights into their operations that the public does not. However, it is crucial for investors to consider insider transactions in the context of broader market trends and additional data points rather than in isolation. The transparency required by the SEC means that such transactions provide valuable insight into how company executives view their stock, but they should be analyzed alongside other fundamental and technical indicators.